Johanna Lähteenvuo et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 28(7), 1731-1740 (2020-04-04)
VEGF-B gene therapy is a promising proangiogenic treatment for ischemic heart disease, but, unexpectedly, we found that high doses of VEGF-B promote ventricular arrhythmias (VAs). VEGF-B knockout, alpha myosin heavy-chain promoter (αMHC)-VEGF-B transgenic mice, and pigs transduced intramyocardially with adenoviral